SCHEMBL19855382

SCHEMBL19855382

C=C(CO)C(=O)Oc1cc(OC(=O)C(=C)CO)cc(-c2ccc(OCC3CCC(CCCCC)CC3)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PARP15 Q460N3 2/20 0.37
▸ PARP10 Q53GL7 2/20 0.37
▸ PARP2 Q9UGN5 2/20 0.37
▸ ACACB O00763 2/20 0.37
▸ ACACA Q13085 1/20 0.37
▸ FFAR4 Q5NUL3 2/20 0.36
▸ PDE4A P27815 2/20 0.36
▸ PDE4D Q08499 2/20 0.36
▸ ITGB3 P05106 2/20 0.35
▸ ITGA2B P08514 2/20 0.35
▸ RARB P10826 4/20 0.35
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ KDM5A P29375 1/20 0.33
▸ KDM2B Q8NHM5 1/20 0.33
▸ KDM4C Q9H3R0 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20313506 0.90 PLA2G2A (0.36) PARP15PARP10PARP2PDE4APDE4D
SCHEMBL19854041 0.90 PLA2G2A (0.36) PARP15PARP10PARP2PDE4APDE4D
SCHEMBL20313538 0.87 KMT2A (0.35) —
SCHEMBL19855547 0.87 CYP2C9 (0.40) —
SCHEMBL19854418 0.87 CYP2C9 (0.40) —
SCHEMBL19854697 0.87 THRB (0.36) FFAR4ITGB3ITGA2BRARB
SCHEMBL19855542 0.84 CYP2C9 (0.38) —
SCHEMBL20313622 0.83 CYP2C9 (0.37) —
SCHEMBL19854653 0.82 MAPT (0.32) —
SCHEMBL19721990 0.81 CYP2C9 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
EP-3351525-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2018-07-25 — — EP disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 — — US disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 — — US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE C1S, CCND1, C5 PARP15 1149/4885PARP10 1178/4885PARP2 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback